Long-Term Results of the Birmingham Hip Resurfacing Implant in the United States: An Updated Analysis of a Single Institution's Experience.

IF 4.4 1区医学 Q1 ORTHOPEDICS

Journal of Bone and Joint Surgery, American Volume Pub Date : 2025-03-19 Epub Date: 2025-02-05 DOI:10.2106/JBJS.24.00926

William A Zuke, Charles P Hannon, Rondek Salih, Joseph Kromka, Caroline Granger, John C Clohisy, Robert L Barrack

{"title":"Long-Term Results of the Birmingham Hip Resurfacing Implant in the United States: An Updated Analysis of a Single Institution's Experience.","authors":"William A Zuke, Charles P Hannon, Rondek Salih, Joseph Kromka, Caroline Granger, John C Clohisy, Robert L Barrack","doi":"10.2106/JBJS.24.00926","DOIUrl":null,"url":null,"abstract":"Background: We previously reported the 5-year results of the Birmingham Hip Resurfacing (BHR) implant. This study evaluates BHR survivorship as well as radiographic and clinical outcomes at long-term follow-up.Methods: A total of 224 patients with contemporary indications, including 179 patients from the original study, were included in this analysis. Survivorship was calculated. Metal ion levels and radiographs were updated. Patient-reported outcomes (PROs) were compared with those for matched patients who had undergone total hip arthroplasty (THA). The mean follow-up was 14 years.Results: Survivorship free from any revision and from aseptic revision was 96.0% and 97.4% at 15 years, respectively. Two patients had undergone revision since the original study. The median serum cobalt and chromium levels were 1.4 and 1.5 ppb, respectively. The PROs were similar to those for the THA cohort. Equal proportions of patients remained active; however, the BHR group trended toward more remaining highly active (p = 0.12).Conclusions: Although activity was similar to THA at long-term follow-up, the BHR implant remains an excellent option for the treatment of osteoarthritis in younger male patients.Level of evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.","PeriodicalId":15273,"journal":{"name":"Journal of Bone and Joint Surgery, American Volume","volume":" ","pages":"e19"},"PeriodicalIF":4.4000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905902/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone and Joint Surgery, American Volume","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2106/JBJS.24.00926","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We previously reported the 5-year results of the Birmingham Hip Resurfacing (BHR) implant. This study evaluates BHR survivorship as well as radiographic and clinical outcomes at long-term follow-up.

Methods: A total of 224 patients with contemporary indications, including 179 patients from the original study, were included in this analysis. Survivorship was calculated. Metal ion levels and radiographs were updated. Patient-reported outcomes (PROs) were compared with those for matched patients who had undergone total hip arthroplasty (THA). The mean follow-up was 14 years.

Results: Survivorship free from any revision and from aseptic revision was 96.0% and 97.4% at 15 years, respectively. Two patients had undergone revision since the original study. The median serum cobalt and chromium levels were 1.4 and 1.5 ppb, respectively. The PROs were similar to those for the THA cohort. Equal proportions of patients remained active; however, the BHR group trended toward more remaining highly active (p = 0.12).

Conclusions: Although activity was similar to THA at long-term follow-up, the BHR implant remains an excellent option for the treatment of osteoarthritis in younger male patients.

Level of evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.

查看原文本刊更多论文

伯明翰髋关节置换术在美国的长期效果：对单一机构经验的最新分析。

背景：我们之前报道了伯明翰髋关节表面置换（BHR）植入物的5年结果。本研究在长期随访中评估BHR的生存率以及影像学和临床结果。方法：共纳入224例具有当代适应症的患者，其中179例来自原始研究。计算生存率。更新了金属离子水平和x光片。将患者报告的结果（PROs）与接受全髋关节置换术（THA）的匹配患者的结果进行比较。平均随访时间为14年。结果：15年无任何翻修和无菌翻修的生存率分别为96.0%和97.4%。自最初的研究以来，有两名患者接受了翻修。血清中钴和铬水平分别为1.4和1.5 ppb。赞成度与全髋关节置换术组相似。同样比例的患者仍然活跃；然而，BHR组更倾向于保持高度活跃（p = 0.12）。结论：尽管在长期随访中活动与THA相似，BHR植入物仍然是治疗年轻男性骨关节炎患者的绝佳选择。证据等级：治疗性III级。有关证据水平的完整描述，请参见作者说明。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Bone and Joint Surgery, American Volume 医学-外科

CiteScore

8.90

自引率

7.50%

发文量

660

审稿时长

1 months

期刊介绍： The Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.